Supplementary Figure 2: CYSLTR2 mutations in TCGA data sets.
From: Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma
(a) Prevalence of CYSLTR2 mutations in TCGA cohorts. (b) Location of all CYSLTR2 mutations in TCGA cohorts. Two amino acids, Leu129 and Arg136, are mutated in more than one sample. There are three p.Leu129Gln mutations, all in uveal melanoma (red arrow), two p.Arg136His mutations (one colorectal and one adrenal cortical), and one p.Arg136Cys mutation (colorectal) (blue arrow). (c) Gene expression of CYSLTR2 in wild-type and mutant samples in selected TCGA cohorts. Data show that, other than p.Leu129Gln in uveal melanoma, CYSLTR2 is not highly expressed in mutated samples in other cancer types. A blue arrow indicates samples with Arg136 mutation. A red arrow indicates samples with p.Leu129Gln mutation. (d) Total mutational count of tumor samples in selected TCGA cohorts in CYSLTR2 wild-type and mutated samples. This highlights the low mutational burden of uveal melanoma. A blue arrow indicates samples with Arg136 mutation. A red arrow indicates samples with Leu129Gln mutation.
